MX2020014086A - Compuestos de aminoácidos con ligadores no ramificados y métodos de uso. - Google Patents
Compuestos de aminoácidos con ligadores no ramificados y métodos de uso.Info
- Publication number
- MX2020014086A MX2020014086A MX2020014086A MX2020014086A MX2020014086A MX 2020014086 A MX2020014086 A MX 2020014086A MX 2020014086 A MX2020014086 A MX 2020014086A MX 2020014086 A MX2020014086 A MX 2020014086A MX 2020014086 A MX2020014086 A MX 2020014086A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- methods
- amino acid
- acid compounds
- unbranched
- Prior art date
Links
- -1 Amino acid compounds Chemical class 0.000 title 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 abstract 2
- 201000004071 non-specific interstitial pneumonia Diseases 0.000 abstract 2
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 102000006495 integrins Human genes 0.000 abstract 1
- 108010044426 integrins Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyrrole Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Devices That Are Associated With Refrigeration Equipment (AREA)
Abstract
La invención se refiere a compuestos de la Fórmula (A): (ver fórmula A) o una sal de estos, en donde R1, R2, R5a, R*, R6a, R6b, R7a, R7b, R8a, R8b, R9a, R9b, R10a, R10b, R11a, R11b, R21, n y G son como se describen en la presente. Los compuestos de la Fórmula (I) y las composiciones farmacéuticas de estos son inhibidores de la integrina aVß6 que son útiles para tratar la fibrosis, tal como la fibrosis pulmonar idiopática (IPF) y la neumonía intersticial inespecífica (NSIP).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862690939P | 2018-06-27 | 2018-06-27 | |
PCT/US2019/039624 WO2020006315A1 (en) | 2018-06-27 | 2019-06-27 | Amino acid compounds with unbranched linkers and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020014086A true MX2020014086A (es) | 2021-04-13 |
Family
ID=68987528
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020014086A MX2020014086A (es) | 2018-06-27 | 2019-06-27 | Compuestos de aminoácidos con ligadores no ramificados y métodos de uso. |
Country Status (21)
Country | Link |
---|---|
US (2) | US11396506B2 (es) |
EP (1) | EP3813818A4 (es) |
JP (2) | JP7425757B2 (es) |
KR (1) | KR20210043561A (es) |
CN (1) | CN112689507A (es) |
AU (1) | AU2019295769B2 (es) |
BR (1) | BR112020026278A2 (es) |
CA (1) | CA3104682A1 (es) |
CL (1) | CL2020003382A1 (es) |
CR (1) | CR20210041A (es) |
CU (1) | CU24693B1 (es) |
DO (1) | DOP2020000255A (es) |
EA (1) | EA202190134A1 (es) |
EC (1) | ECSP21005655A (es) |
IL (2) | IL308960A (es) |
JO (1) | JOP20200330A1 (es) |
MX (1) | MX2020014086A (es) |
PE (1) | PE20210137A1 (es) |
PH (1) | PH12020552260A1 (es) |
SG (1) | SG11202013027RA (es) |
WO (1) | WO2020006315A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109996541A (zh) | 2016-09-07 | 2019-07-09 | 普利安特治疗公司 | N-酰基氨基酸化合物及其使用方法 |
US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
JP2020504120A (ja) | 2016-12-29 | 2020-02-06 | セントルイス ユニバーシティ | インテグリンアンタゴニスト |
RU2769702C2 (ru) | 2017-02-28 | 2022-04-05 | Морфик Терапьютик, Инк. | Ингибиторы интегрина avb6 |
EP3760202A1 (en) | 2017-02-28 | 2021-01-06 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
CR20200452A (es) | 2018-03-07 | 2020-11-19 | Pliant Therapeutics Inc | Compuestos de aminoacidos y métodos de uso |
KR20210024586A (ko) | 2018-06-27 | 2021-03-05 | 브리스톨-마이어스 스큅 컴퍼니 | T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물 |
BR112020026278A2 (pt) | 2018-06-27 | 2021-04-06 | Pliant Therapeutics, Inc. | Compostos de aminoácidos com ligantes não ramificados e métodos de uso |
EP4086254A1 (en) | 2018-08-29 | 2022-11-09 | Morphic Therapeutic, Inc. | Integrin inhibitors |
TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
AU2020273158A1 (en) | 2019-04-08 | 2021-11-11 | Pliant Therapeutics, Inc. | Dosage forms and regimens for amino acid compounds |
US20230055657A1 (en) * | 2019-12-20 | 2023-02-23 | Novartis Ag | Combination treatment of liver diseases using integrin inhibitors |
CA3164941A1 (en) * | 2019-12-20 | 2021-06-24 | Novartis Ag | Combination treatment of liver diseases using integrin inhibitors |
GB202209228D0 (en) | 2022-06-23 | 2022-08-10 | Univ Strathclyde | Modified amino acids and uses thereof |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69829996T2 (de) * | 1997-12-17 | 2006-02-23 | Merck & Co., Inc. (A New Jersey Corp.) | Integrin-rezeptor-antagonisten |
US6048861A (en) | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
US6329372B1 (en) * | 1998-01-27 | 2001-12-11 | Celltech Therapeutics Limited | Phenylalanine derivatives |
AR059224A1 (es) * | 2006-01-31 | 2008-03-19 | Jerini Ag | Compuestos para la inhibicion de integrinas y uso de estas |
JP2009539815A (ja) * | 2006-06-09 | 2009-11-19 | アストラゼネカ アクチボラグ | 固形腫瘍の治療用のa5b1アンタゴニストとしてのN−(ベンゾイル)−O−[2−(ピリジン−2−イルアミノ)エチル]−L−チロシン誘導体と関連化合物 |
WO2008093064A1 (en) * | 2007-01-29 | 2008-08-07 | Astrazeneca Ab | L-ALANINE DERIVATIVES AS α5 BETA 1 ANTAGONISTS |
GB201305668D0 (en) * | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
WO2015048819A1 (en) | 2013-09-30 | 2015-04-02 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
AU2016228852A1 (en) | 2015-03-10 | 2017-10-19 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
CN104817604B (zh) | 2015-03-16 | 2017-08-04 | 邦泰生物工程(深圳)有限公司 | 一种β‑烟酰胺单核苷酸的纯化方法 |
JP2018514568A (ja) * | 2015-04-30 | 2018-06-07 | サイフルーア ライフ サイエンシズ インコーポレイテッド | テトラヒドロナフチリジニルプロピオン酸誘導体およびその使用法 |
WO2018009501A1 (en) | 2016-07-05 | 2018-01-11 | The Rockefeller University | Tetrahydronaphthyridinepentanamide integrin antagonists |
CN109996541A (zh) * | 2016-09-07 | 2019-07-09 | 普利安特治疗公司 | N-酰基氨基酸化合物及其使用方法 |
MA46744A (fr) * | 2016-11-08 | 2019-09-18 | Bristol Myers Squibb Co | Composés mono et spirocycliques contenant du cyclobutane et de l'azétidine en tant qu'inhibiteurs de l'intégrine alpha v |
US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
RU2769702C2 (ru) | 2017-02-28 | 2022-04-05 | Морфик Терапьютик, Инк. | Ингибиторы интегрина avb6 |
EP3760202A1 (en) * | 2017-02-28 | 2021-01-06 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
CR20200452A (es) | 2018-03-07 | 2020-11-19 | Pliant Therapeutics Inc | Compuestos de aminoacidos y métodos de uso |
BR112020026278A2 (pt) | 2018-06-27 | 2021-04-06 | Pliant Therapeutics, Inc. | Compostos de aminoácidos com ligantes não ramificados e métodos de uso |
EP4086254A1 (en) | 2018-08-29 | 2022-11-09 | Morphic Therapeutic, Inc. | Integrin inhibitors |
WO2020047207A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutics, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
AU2020273158A1 (en) | 2019-04-08 | 2021-11-11 | Pliant Therapeutics, Inc. | Dosage forms and regimens for amino acid compounds |
US20210147526A1 (en) | 2019-11-15 | 2021-05-20 | Pliant Therapeutics, Inc. | Compositions and methods for activation of integrins |
KR20230049584A (ko) | 2020-05-07 | 2023-04-13 | 플라이언트 테라퓨틱스, 인크. | 아미노산 화합물을 사용한 호흡기 질환의 치료 |
CA3173755A1 (en) | 2020-11-19 | 2022-05-27 | Pliant Therapeutics, Inc. | Integrin inhibitor and uses thereof |
JP2024517765A (ja) | 2021-04-30 | 2024-04-23 | プライアント・セラピューティクス・インコーポレイテッド | インテグリン阻害剤の拡大投与レジメン |
WO2023035000A1 (en) | 2021-09-03 | 2023-03-09 | Pliant Therapeutics, Inc. | Therapeutic modulation of integrins |
CA3234791A1 (en) | 2021-10-14 | 2023-04-20 | Eric Lefebvre | Integrin inhibitors and uses thereof in combination with other agents |
-
2019
- 2019-06-27 BR BR112020026278-1A patent/BR112020026278A2/pt unknown
- 2019-06-27 WO PCT/US2019/039624 patent/WO2020006315A1/en active Application Filing
- 2019-06-27 EP EP19826330.3A patent/EP3813818A4/en active Pending
- 2019-06-27 AU AU2019295769A patent/AU2019295769B2/en active Active
- 2019-06-27 JP JP2020572976A patent/JP7425757B2/ja active Active
- 2019-06-27 MX MX2020014086A patent/MX2020014086A/es unknown
- 2019-06-27 IL IL308960A patent/IL308960A/en unknown
- 2019-06-27 CU CU2021000001A patent/CU24693B1/es unknown
- 2019-06-27 CR CR20210041A patent/CR20210041A/es unknown
- 2019-06-27 KR KR1020217002250A patent/KR20210043561A/ko active Search and Examination
- 2019-06-27 CN CN201980050125.6A patent/CN112689507A/zh active Pending
- 2019-06-27 CA CA3104682A patent/CA3104682A1/en active Pending
- 2019-06-27 US US16/455,490 patent/US11396506B2/en active Active
- 2019-06-27 PE PE2020002165A patent/PE20210137A1/es unknown
- 2019-06-27 JO JOP/2020/0330A patent/JOP20200330A1/ar unknown
- 2019-06-27 IL IL279717A patent/IL279717B2/en unknown
- 2019-06-27 EA EA202190134A patent/EA202190134A1/ru unknown
- 2019-06-27 SG SG11202013027RA patent/SG11202013027RA/en unknown
-
2020
- 2020-12-23 PH PH12020552260A patent/PH12020552260A1/en unknown
- 2020-12-23 DO DO2020000255A patent/DOP2020000255A/es unknown
- 2020-12-23 CL CL2020003382A patent/CL2020003382A1/es unknown
-
2021
- 2021-01-26 EC ECSENADI20215655A patent/ECSP21005655A/es unknown
-
2022
- 2022-02-23 US US17/679,002 patent/US11858931B2/en active Active
-
2024
- 2024-01-19 JP JP2024006536A patent/JP2024055873A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020014086A (es) | Compuestos de aminoácidos con ligadores no ramificados y métodos de uso. | |
MX2022014456A (es) | Compuestos de aminoacidos y metodos de uso. | |
MX2021004015A (es) | Compuestos de aminoacidos y metodos de uso. | |
PH12018501956A1 (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
TN2018000106A1 (en) | Farnesoid x receptor modulators | |
MX361488B (es) | Cocristales de (s)-n-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il ) amino)propan-2-il)quinolina-4-carboxamida y sus derivados deuterados como inhibidores de proteínas cinasa dependientes de adn (adn-pk). | |
WO2017205536A3 (en) | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer | |
EA201492285A1 (ru) | Соединения n-алкилтриазола в качестве антагонистов лизофосфатидной кислоты (lpar) | |
EA201101672A1 (ru) | Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина | |
EA202090413A1 (ru) | Пиразоло- и триазолобициклические соединения в качестве ингибиторов jak киназы | |
HK1121749A1 (en) | Benzamide compounds useful as histone deacetylase inhibitors | |
MX2021014113A (es) | Derivados de aminoquinazolina como inhibidores del purinoreceptor 3 de p2x (p2x3). | |
EA201101301A1 (ru) | Натриевая соль 5-циклопропил-2-{[2-(2,6-дифторфенил)пиримидин-5-ил]амино}бензойной кислоты в качестве ингибиторов dhodh | |
EA201492283A1 (ru) | Замещенные соединения пиразола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar) | |
MX2020005841A (es) | Derivados de 1,2,4-oxadiazol como inhibidores de histona-desacetilasa 6. | |
EA201891506A1 (ru) | Индолиноновые соединения и их применение в лечении фиброзных заболеваний | |
MX2018008439A (es) | Orvepitant para el tratamiento de la tos cronica. | |
EA201892020A1 (ru) | Индольные производные и их применение в качестве ингибиторов протеинкиназы | |
PH12020500204A1 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic disease | |
EA202092110A1 (ru) | Аминокислотные соединения и способы применения | |
PH12020500385A1 (en) | A process for preparation of triaminopyrimidine compound and intermediates thereof | |
MX2017017151A (es) | Nuevas fases solidas de inhibidores de la reabsorcion osea. |